GlassScriptPhysician profile
Jason F White
NPI 1508974841
$6,407.60
in general payments reported to CMS, 2019-2025
34 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $190 · 2021: $939 · 2022: $1,159 · 2023: $1,104 · 2024: $960 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,020.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $721.46 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $716.35 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $632.25 | 2019-2025 | Dupixent |
| Genzyme Corporation | $590.94 | 2019-2025 | |
| Amgen INC. | $304.45 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $259.50 | 2020-2025 | Xolair |
| Galderma Laboratories, L.P. | $223.22 | 2025 | Nemluvio |
| Grifols USA, LLC | $178.28 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $165.79 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $161.44 | 2021-2025 | Orladeyo |
| Aerin Medical INC. | $148.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.95 | 2021-2025 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $120.39 | 2021-2022 | |
| Pharming Healthcare, INC. | $117.04 | 2021-2024 | Ruconest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $105.99 | 2025 | Neffy |
| Kaleo, INC. | $104.08 | 2019-2021 | |
| Covis Pharma Gmbh | $98.51 | 2021-2022 | |
| Blueprint Medicines Corporation | $71.63 | 2023-2025 | Ayvakit |
| Pfizer INC. | $69.85 | 2019-2022 | |
| Abbvie INC. | $65.15 | 2022-2023 | Rinvoq |
| Alk-Abello, INC | $43.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $43.50 | 2021 | |
| Verona Pharma, INC. | $40.85 | 2025 | Ohtuvayre |
| Optinose US, INC. | $37.38 | 2022-2024 | |
| Lilly USA, LLC | $34.61 | 2024-2025 | Ebglyss |
| Lundbeck LLC | $32.55 | 2019-2025 | Vyepti |
| Aimmune Therapeutics, INC. | $26.85 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.66 | 2021 | |
| Mirum Pharmaceuticals, INC. | $24.00 | 2025 | Cholbam |
| Hospira, INC. | $23.46 | 2024 | |
| Paratek Pharmaceuticals, INC. | $22.02 | 2025 | Xhance, Nuzyra |
| Octapharma USA, INC. | $18.57 | 2024 | Cutaquig |
| Merck Sharp & Dohme LLC | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.